Folic acid(Synonyms: 叶酸; Vitamin B9; Vitamin M)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Folic acid (Synonyms: 叶酸; Vitamin B9; Vitamin M) 纯度: 99.56%

Folic acid(Vitamin M; Vitamin B9)是维生素B9。

Folic acid(Synonyms: 叶酸; Vitamin B9;  Vitamin M)

Folic acid Chemical Structure

CAS No. : 59-30-3

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
500 mg ¥500 In-stock
5 g ¥600 In-stock
10 g ¥960 In-stock
50 g   询价  

* Please select Quantity before adding items.

Folic acid 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Peptidomimetic Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Anti-COVID-19 Compound Library
  • NMPA-Approved Drug Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Gut Microbial Metabolite Library
  • Microbial Metabolite Library
  • Food Additive Library
  • Food-Sourced Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Folic acid(Vitamin M; Vitamin B9) is a B vitamin; is necessary for the production and maintenance of new cells, for DNA synthesis and RNA synthesis.

IC50 & Target

Human Endogenous Metabolite

 

Clinical Trial

分子量

441.40

Formula

C19H19N7O6

CAS 号

59-30-3

中文名称

叶酸;维生素 B9;维生素 M

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

1M NaOH : 100 mg/mL (226.55 mM; Need ultrasonic)

DMSO : 33.33 mg/mL (75.51 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2655 mL 11.3276 mL 22.6552 mL
5 mM 0.4531 mL 2.2655 mL 4.5310 mL
10 mM 0.2266 mL 1.1328 mL 2.2655 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (4.71 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (4.71 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

NH2-PEG3-C2-Boc

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

NH2-PEG3-C2-Boc 

NH2-PEG3-C2-Boc 是一种 PROTAC linker,属于 PEG 类。可用于合成 PROTAC 分子。

NH2-PEG3-C2-Boc

NH2-PEG3-C2-Boc Chemical Structure

CAS No. : 252881-74-6

规格 价格 是否有货 数量
250 mg ¥800 In-stock
500 mg ¥1200 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

生物活性

NH2-PEG3-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC50 & Target

PEGs

 

体外研究
(In Vitro)

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

277.36

Formula

C13H27NO5

CAS 号

252881-74-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献
  • [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

环境分析纯试剂|试剂|关东化学株式会社

弹出窗口打开

室内环境・作业环境分析

试剂的咨询

信息查询

电话: 03 – 6214 – 1090

传真: 03 – 3241 – 1047

该文章由WP-AutoPost插件自动采集发布

原文地址:http://translate.baiducontent.com/transpage?cb=translateCallback&ie=utf8&source=url&query=http%3A%2F%2Fwww.kanto.co.jp%2Fproducts%2Fsiyaku%2Fenvironmental_analysis%2Findex.html&from=jp&to=zh&token=&monLang=zh

Tesirine(Synonyms: SG3249)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Tesirine (Synonyms: SG3249) 纯度: 97.96%

Tesirine (SG3249) 是一种抗体偶联药物 (ADC) 的吡咯苯并二氮卓 (PBD) 二聚体。Tesirine 结合了抗肿瘤活性和理想的物理化学性质,如良好的疏水性和改进的共轭特性。SG3199 (HY-101161) 是 ADC 有效载荷 Tesirine 的释放弹头成分。SG3199 在一组癌细胞系中保持皮摩尔活性。PBD 二聚体是一种高效的 DNA 小沟交联剂,具有很强的细胞毒性。

Tesirine(Synonyms: SG3249)

Tesirine Chemical Structure

CAS No. : 1595275-62-9

规格 价格 是否有货 数量
1 mg ¥19200 In-stock
5 mg ¥64000 In-stock
10 mg ¥105000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity[1][2].

IC50 & Target

Pyrrolobenzodiazepines

 

体外研究
(In Vitro)

SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 inhibits K562, NCIN87, BT474, and SKBR3 cancer cells with IC50s of 150 pM, 20 pM, 1 nM and 320 pM[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1496.65

Formula

C75H101N9O23

CAS 号

1595275-62-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶解性数据
In Vitro: 

DMSO : 200 mg/mL (133.63 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.6682 mL 3.3408 mL 6.6816 mL
5 mM 0.1336 mL 0.6682 mL 1.3363 mL
10 mM 0.0668 mL 0.3341 mL 0.6682 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 5 mg/mL (3.34 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (3.34 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic

    此方案可获得 5 mg/mL (3.34 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 5 mg/mL (3.34 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (3.34 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Tiberghien AC, et al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016;7(11):983-987. Published 2016 May 24.

    [2]. Hartley JA, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. Published 2018 Jul 11.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Monensin sodium salt(Synonyms: Monensin A sodium salt)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Monensin sodium salt (Synonyms: Monensin A sodium salt) 纯度: ≥98.0%

Monensin sodium salt 是由肉桂链霉菌 (Streptomyces cinnamonensis) 分泌的抗生素。Monensin sodium salt 是一种介导 Na+/H+ 交换的离子载体。Monensin sodium salt 引起细胞多泡体 (MVBs) 增大并调节外泌体的分泌。

Monensin sodium salt(Synonyms: Monensin A sodium salt)

Monensin sodium salt Chemical Structure

CAS No. : 22373-78-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in Ethanol ¥440 In-stock
100 mg ¥400 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Monensin sodium salt 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Antibacterial Compound Library
  • Medicine Food Homology Compound Library
  • Antibiotics Library
  • Exosomes Compound Library
  • Microbial Metabolite Library

生物活性

Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Monensin sodium salt is an ionophore that mediates Na+/H+ exchange. Monensin sodium salt causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion[1][2][3][4].

IC50 & Target

bacterial[1]

体外研究
(In Vitro)

Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Untreated cells display 2.5% apoptosis; 48 hours treatment with 1 μM Monensin sodium salt shows 4.5% apoptosis whereas 5 μM Monensin sodium salt for 48 hours induces a greater apoptotic response (16.4%). Pretreatment with either 1 or 5 μM Monensin sodium salt for 24 hours followed by 10 μM erlotinib treatment for another 24 hours results in a marked increases in apoptotic events (14.6% and 38.7%, respectively) when compare with either Monensin sodium salt or erlotinib treatments alone. Combination of 5 μM Monensin sodium salt with 10 μM erlotinib shows the highest percentage of apoptosis (38.7%)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Although the numbers of tumors do not change substantially, a significant (P=0.0144) reduction in the average size of lesions is observed in Monensin sodium salt-treated Apc+/Min mice when compare with control animals (mean 0.199 mm2 vs. 0.299 mm2). The total tumor area estimated in one animal is decreased in individuals receiving Monensin sodium salt (mean 10.16 mm2 vs. 16.46 mm2; P=0.0125). Monensin sodium salt treatment increases the numbers of apoptotic cells and cells expressing the p21 cell-cycle inhibitor at the surface area of the neoplastic outgrowths. No changes in the cell proliferation, differentiation, and tissue architecture in the healthy parts of mucosa are noted after exposure to Monensin sodium salt[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

692.85

Formula

C36H61NaO11

CAS 号

22373-78-0

中文名称

莫能菌素钠盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

Ethanol : 20 mg/mL (28.87 mM; Need ultrasonic)

DMSO : 5.4 mg/mL (7.79 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4433 mL 7.2166 mL 14.4331 mL
5 mM 0.2887 mL 1.4433 mL 2.8866 mL
10 mM 0.1443 mL 0.7217 mL 1.4433 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% EtOH    90% corn oil

    Solubility: ≥ 2 mg/mL (2.89 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (2.89 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.

    [2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.

    [3]. Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front. Microbiol., 30 April 2020.

    [4]. Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43.

Cell Assay
[1]

One million SCC25 cells are seeded in 10-cm plates and incubated overnight to allow for attachment and recovery. The following day, cells are pretreated with 0, 1, or 5 μM Monensin sodium salt for 24 hours then treated with 10 μM erlotinib alone or in combination with Monensin sodium salt for a further 24 hours. Adherent and cells in suspension are collected by centrifugation and fixed in 3 mL of cold 80% ethanol overnight at -20°C. Before analysis, cell pellets are washed with PBS resuspended in staining buffer containing 25 μg/mL propidium iodide and 40 μg/mL RNase A and incubated for a minimum of 1 hour in the dark at room temperature[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Multiple intestinal neoplasia (Min) mice are used in this study. Four-week-old pups are weaned, genotyped, and randomized. The animals are divided into two groups and treated with Monensin sodium salt (10 mg/kg) or vehicle (DMSO). Daily oral applications continue for 6 weeks. In addition, six pairs of Apc+/Min mice age 7, 10, 13, 16, 19, and 22 weeks are treated with Monensin sodium salt or vehicle for 5 weeks. The mice are sacrificed and the intestines are dissected, washed in PBS, and fixed in 4% formaldehyde (v/v) in PBS for 3 days. Fixed intestines are embedded in paraffin, sectioned and stained. The number and size of the neoplastic lesions are quantified using Ellipse software[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.

    [2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.

    [3]. Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front. Microbiol., 30 April 2020.

    [4]. Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

MC-VC-PAB-NH2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

MC-VC-PAB-NH2 

MC-VC-PAB-NH2 是一种可降解 (cleavable) 的 ADC linker,可用于合成抗体偶联药物 (ADC)。

MC-VC-PAB-NH2

MC-VC-PAB-NH2 Chemical Structure

CAS No. : 1616727-20-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

MC-VC-PAB-NH2 is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

IC50 & Target

Cleavable

 

体外研究
(In Vitro)

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

658.75

Formula

C31H46N8O8

CAS 号

1616727-20-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

药品自动供给装置|电子材料|关东化学株式会社

弹出窗口打开

药品自动供给装置

电子对材料的咨询

信息查询

电话: 03 – 6214 – 1080

传真: 03 – 3241 – 1043

该文章由WP-AutoPost插件自动采集发布

原文地址:http://translate.baiducontent.com/transpage?cb=translateCallback&ie=utf8&source=url&query=http%3A%2F%2Fwww.kanto.co.jp%2Fproducts%2Fdenshi%2Fsouchi%2Findex.html&from=jp&to=zh&token=&monLang=zh

SID 26681509

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SID 26681509  纯度: 98.26%

SID 26681509 是一种有效的,可逆的,竞争性的,选择性的人组织蛋白酶 L (human cathepsin L) 抑制剂,IC50 为 56 nM。SID 2668150 抑制 Plasmodium falciparum 的体外繁殖,并抑制 Leishmania majorIC50 分别为 15.4 μM 和 12.5 μM。SID 26681509 对组织蛋白酶 G 没有抑制活性。

SID 26681509

SID 26681509 Chemical Structure

CAS No. : 958772-66-2

规格 价格 是否有货 数量
1 mg ¥1950 In-stock
5 mg ¥5800 In-stock
10 mg ¥9800 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

SID 26681509 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G[1].

IC50 & Target

IC50: 56 nM (Human cathepsin L), 0.5 μM (Cathepsin V), 15.4 μM (Plasmodium falciparum), 12.5 μM (Leishmania major)[1]

体外研究
(In Vitro)

After a 4 hr preincubation with cathepsin L, SID 26681509 becomes more potent, demonstrating an IC50 of 1.0 nM. SID 26681509 is determined to be a slow-binding and slowly reversible competitive inhibitor. Through a transient kinetic analysis for single-step reversibility, inhibition rate constants are kon = 24,000 M-1s-1 and koff = 2.2 × 10-5 s-1 (Ki = 0.89 nM). Molecular docking studies are undertaken using the experimentally-derived X-ray crystal structure of papain/CLIK-148[1].
SID 26681509 inhibits papain and cathepsins B, K, S, and V with IC50 values determined after one hour ranging from 618 nM to 8.442 μM. SID 26681509 shows no inhibitory activity against the serine protease cathepsin G[1].
SID 26681509 inhibits cathepsin V activity with an IC50 value of 0.5 μM. SID 26681509 (1-30 μM) blocks high-mobility group box 1 (HMGB1)-induced TNF-α production dose dependently without altering cell viability[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

SID 26681509 treatment significantly improves survival in murine models of sepsis and reduces liver damage following warm liver ischemia/reperfusion (I/R) models[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

539.65

Formula

C27H33N5O5S

CAS 号

958772-66-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
  • [1]. Shah PP, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol. 2008 Jul;74(1):34-41.

    [2]. Pribis JP, et al. The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Mol Med. 2015 Dec;21(1):749-757.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务